Tysabri

Tysabri Lawyers Pulaski & Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects

Houston-based Law Firm Offers Assistance, Information to People Affected by Dangerous Tysabri Effects. Houston, TX (PRWEB) August 2, 2008 -- Tysabri side effects lawyers Pulaski & Middleman announce the launch of a http://www.tysabrilawsuitattorney.com [website] d...

MS Drug Tysabri Approved for Crohn's Disease

But the drug comes with serious risks, FDA notes MONDAY, Jan. 14 (HealthDay News) -- Tysabri, a controversial drug used to treat multiple sclerosis, may also be used for patients with a moderate to severe form of another autoimmune illness, Crohn's disease, the U.S. Food and Drug Admin...

Stopping Tysabri May Worsen MS

Small study finds increase in disease-linked brain lesions THURSDAY, Sept. 13 (HealthDay News) -- People suffering from multiple sclerosis who stopped taking the controversial drug Tysabri experienced a resurgence of brain lesions associated with their disease, researchers report. B...

MS patients report greater treatment satisfaction with TYSABRI

Atlanta, Ga. May 28, 2009 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced interim results from an ongoing, one-year longitudinal health-outcomes study in which patients reported significantly higher levels of treatment satisfaction after three infusions with TYSA...

Multiple Sclerosis drug, Tysabri banned due to neurological disorders

Tysabri, which is used in the treatment of Multiple Sclerosis (MS), has been withdrawn from market after the two patients taking the drug complained of neurological disorders. The relationship between the drug and // Progressive Multifocal Leukoencephalopathy (PML) is being researched by the scient...

Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis

Recently the Food and Drug Administration (FDA) issued a public health advisory to inform patients and health care // providers about the suspended marketing of Tysabri (nataluzimab) the drug meant to treat relapsing forms of multiple sclerosis (MS) which was approved by the FDA in 2004. FDA...

PDL BioPharma Announces Second Quarter 2009 Financial Results

...approximately 50 percent of underlying product sales is in currencies other than U.S. dollars. "We have seen significant increases in sales of tysabri and other products in our licensing portfolio, demonstrating that these products are fulfilling the promise of the underlying humanization technology,...

Aurora Physician Recognized for Multiple Sclerosis Care

...benefits of plasma exchange for treating multiple sclerosis at the American Academy of Neurology annual meeting. In addition, his research on the drug tysabri was published in Neurology , an American Academy of Neurology journal. The National Multiple Sclerosis Society estimates 400,000 people in the ...

MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR

...han one-third of the patients used Avonex as index medication, while others used Copaxone (31 percent), Rebif (17 percent), Betaseron (14 percent) and tysabri (less than 1 percent). About HealthCore HealthCore, based in Wilmington, Del., is the clinical outcomes research subsidiary of WellPoint. He...

Tysabri May Treat Myelin Sheath Damage From MS

... TUESDAY, April 28 (HealthDay News) -- The drug tysabri (natalizumab) appears to regenerate and stabilize ...r 12 months of follow-up, the 62 patients who took tysabri showed remyelination when compared to the 26 who t... "What we have seen in these MRI data suggest that tysabri may have the capacity to repair and possibly resto...

Tysabri in Medical Technology

Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of Tysabri in Patients with Multiple Sclerosis

BOSTON--(BUSINESS WIRE)--May 3, 2007 - Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that new data from the TOUCH Prescribing Program(TM) and TYGRIS safety study confirm the safety profile from previous clinical studies of TYSABRI(R) (natalizumab). Also presented ...

Tysabri in Biological Technology

Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri

SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) thera...